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The constitutively active protein glycogen synthase kinase 3 (GSK3), a serine/threonine
kinase, acts paradoxically as a tumor suppressor in some cancers while potentiates growth
in others. Deciphering what governs its actions is vital for understandingmany pathological
conditions, including brain cancer.What are seemingly disparate roles of GSK3 stems from
the complex regulation of many cellular functions by GSK3.This review focuses on the reg-
ulation of GSK3, its role in survival, apoptosis and DNA damage, and ﬁnally its potential
therapeutic impact in brain cancer. A thorough understanding of this versatile protein is
critical for improving the outcome of various diseases, especially cancer.
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INTRODUCTION
Glycogen synthase kinase 3 (GSK3) has been shown over the past
three decades to regulate a myriad of cellular functions includ-
ing cell polarity, cell fate, metabolic homeostasis, development,
apoptosis, microtubule function, and neuronal growth and dif-
ferentiation. Elegant cellular checkpoints and highly regulated
equilibrium of protein levels are responsible for the precise control
of GSK3 activity. GSK3, while involved in many critical functions,
still remains a nearly untapped source of modulation therapeuti-
cally. The emergence of GSK3 as an attractive therapeutic agent
could stem from its involvement in several of the critical signal-
ing pathways. Multiple genes involved in these pathways are often
susceptible to activating mutations which lead to multiple tumor
types and/or tumor resistance (Brugge et al., 2007). By targeting
GSK3,one could potentially attenuate these dysregulated pathways
to improve tumor response in patients.
More importantly, GSK3 inhibition may also impact quality
of life. The standard curative treatment regimen for primary and
metastatic brain tumors typically involves cranial irradiation (IR),
which often results in long-term neurological side effects, espe-
cially in the pediatric population (Roman and Sperduto, 1995;
Anderson et al., 2000; Boehme et al., 2008). There have been
reports of intellectual impairment, reduction in performance IQ,
memory loss, and dementia after exposure of the brain to radi-
ation. This cognitive decline observed may be due to IR-induced
damage to the hippocampus, a critical area of the brain responsible
for learning and memory (Yazlovitskaya et al., 2006). Consistent
with these ﬁndings, radiation to the hippocampus is associated
with more pronounced cognitive deﬁcits compared with radiation
to other areas of the brain (Abayomi, 2002). As GSK3 inhibition
has been shown to protect neurocognitive function following cra-
nial irradiation, the therapeutic value of GSK3 in cancer may also
be related, in part, to its effects on DNA repair and its emerging
role in neuroprotection of normal neuronal tissues from radia-
tion induced apoptosis (Thotala et al., 2008; Yang et al., 2009,
2011). These combined effects of GSK3 inhibition, namely induc-
ing tumor cell death while protecting normal cells, again make
GSK3 an attractive therapeutic target for brain tumors.
In this review, we will discuss the rationale for therapeutic tar-
geting of GSK3 in oncology, due to the involvement of GSK3 in
apoptosis, DNA damage/repair, and autophagy. Obstacles to tar-
geting GSK3 include its varied and highly regulated role in cellular
homeostasis in addition to the existence of highly homologous
GSK3 isoforms, which will be discussed. Despite these hurdles,
GSK3 nevertheless has been tagged as a potential target in human
cancers, and more importantly, as a protector of normal tissues at
high risk for treatment-related side effects. These characteristics
may ultimately improve the therapeutic ratio and enhance patient
quality of life.
GSK3 MODULATION OF TUMORIGENIC SIGNALS
Glycogen synthase kinase 3 is essentially expressed ubiquitously in
all mammalian tissues and is almost always in an active state in
cells, even when not stimulated by mitogenic or hormonal signals.
There are two mammalian GSK3 isoforms encoded by distinct
genes: GSK3α and GSK3β. GSK3α and GSK3β, although struc-
turally similar, are functionally diverse. GSK3α and GSK3β are
highly conserved and widely expressed kinases that share 98%
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sequence homology within their catalytic domains. Interestingly,
loss of GSK3β isoform is embryonically lethal due to liver degen-
eration caused by extensive hepatocyte apoptosis (Hoeﬂich et al.,
2000). Moreover, GSK3α is unable to rescue this phenotype. It is
alsowell established thatGSK3 activity is regulated primarily at the
posttranslational level, chieﬂy by protein–protein interactions or
posttranslational modiﬁcations (Cohen and Frame, 2001). Phos-
phorylation of GSK3 N-terminally at S9 lowers its activity toward
its substrates (Cohen and Frame, 2001). We refer the readers to
some excellent reviews in this special issue for further details on
GSK3, including its isoforms, regulation of these isoforms, and
their distinct functions.
Dysregulation inGSK3 activity has been linked tomultiple can-
cers. However, the direction by which GSK3 is dysregulated, i.e.,
suppressed vs. activated, is heterogeneous among tumor types as
discussed below. In general, GSK3 primarily functions by inac-
tivating its substrates via phosphorylation, thus altering their
conformation, localization, and/or degradation (Figures 1 and 2).
This, in turn, can affect the subsequent ability of these substrates
to interact and trigger downstream signaling events. Usually, the
substrates of GSK3 need to be “primed” by a separate kinase to
allow GSK3 to bind and subsequently phosphorylate the target
molecule. Here we look at the direct and indirect roles of GSK3 in
cancer.
DIRECT ROLES OF GSK3 IN CANCER
Though various roles of GSK3 in cancer have been proposed, the
direct vs. indirect roles of GSK3 in this disease are difﬁcult to tease
out due to the embryonic lethality of GSK3 loss. In addition, the
signiﬁcant cross talk between different signaling pathways and var-
ied role of GSK3 in these pathways makes it all the more difﬁcult
to pinpoint one player. However, we will detail in the next section
the direct roles of GSK3 in cancer as reported in the literature.
Expression of GSK3β is drastically diminished in multiple can-
cers as listed in Table 1. Ma et al. (2007) have demonstrated
that normal patient skin tissue specimens express higher GSK3β
and pGSK3β expression when compared to cancer. Moreover,
FIGURE 1 | Glycogen synthase kinase 3 modulates the function of key
signaling proteins in the wnt pathway.
utilizing different constructs, they show thatmodulationof GSK3β
activity negatively regulates epidermal cell transformation. In the
complexwebunderlying skin tumorigenesis and involving interac-
tions among multiple signaling cascades and various transcription
factors, GSK3β appears to be an important component in the sig-
naling cascade since modulation of GSK3β expression/activity is
sufﬁcient to alter the transformation potential of epidermal cells.
Thus, GSK3β is a target for skin cancer prevention and treatment
strategies.
Interestingly, in pancreatic cancer, pharmacological inhibition
of GSK3 decreased proliferation and survival of these cancer cells
(Ougolkov et al., 2005). The mechanism was shown to be related
to blockade of GSK3β-mediated upregulation of NF-κB-mediated
gene transcription. Similarly, brain, bladder, colorectal, myeloma,
leukemia, and stomach cancers were also responsive to inhibition
of GSK3 (Mishra, 2010; Naito et al., 2010). For example, phar-
macological inhibition of GSK3 downregulated BCL-2 and XIAP
protein expression levels leading to decreased survival of blad-
der cancer cells. Furthermore, aberrant nuclear accumulation of
GSK3β in urothelial and bladder cancer was observed. Nuclear
expression of GSK3β has been associated with high grade tumors,
metastasis and worse survival in bladder cancer patients and thus
may be a prognostic marker for this cancer (Naito et al., 2010).
In addition,GSK3 inhibition has been shown to promote apop-
tosis in leukemic cells via modulation of chromatin structure
through histone modiﬁcations that abrogate the transcriptional
activity of NFκB (Ougolkov et al., 2007). GSK3 can also promote
mixed lineage leukemia (MLL) cell proliferation and transforma-
tion via destabilization of the cyclin-dependent kinase inhibitor
p27Kip1 (Wang et al., 2008). Similarly, inhibition of GSK3β has
been shown to promote apoptosis in neuroblastoma by pro-
moting G2/M cell cycle arrest, accumulation of β-catenin and
subsequent inhibition of NFκB activity (Dickey et al., 2011). Fur-
thermore, recent studies inprostate,pancreatic,and colorectal can-
cer cell lines indicate that GSK3 inhibitors signiﬁcantly decrease
cell growth and proliferation (Martinez et al., 2006). Thus, taken
FIGURE 2 | Glycogen synthase kinase 3 modulates multiple signaling
pathways involved in carcinogenesis.
Frontiers in Molecular Neuroscience www.frontiersin.org November 2011 | Volume 4 | Article 47 | 2
Mills et al. GSK3 and brain cancer
Table 1 | Evidence for GSK3 involvement in distinct cancers.
Evidence Cancers References
Active GSK3β promotes growth
and inhibition of GSK3 decreases
cell growth and proliferation of
cancer cells
Colorectal Mishra (2010)
Leukemia Ougolkov et al. (2005)
Liver Aijing Sun et al. (2007)
Pancreas Tiebang Kang et al. (2008)
Prostate Mai et al. (2006)
Renal Adler et al. (2009)
Stomach
Thyroid
High level of expression and
nuclear accumulation of GSK3 is
associated with kinase activity
and tumor dedifferentiation
Pancreas Ougolkov et al. (2005)
Pharmacological inhibition of
GSK3 has been shown to
promote cell death (apoptosis)
Brain Zhou et al. (2008)
Colorectal Mishra (2010)
Myeloma Thotala et al. (2008)
Pancreas Mai et al. (2006)
Stomach
Higher pGSK3β (Ser9)
expression is observed,
indicative of inactivated GSK3β
Colorectal Leis et al. (2002)
Lung Tiebang Kang et al. (2008)
Oral Tian et al. (2006)
Skin
together, these results suggest GSK3 as a potential new therapeutic
target in human cancer.
In the brain speciﬁcally, cancers result from abnormal cell
growth and may arise from different cell lineages: neuronal or
glial progenitor cells. Medulloblastomas originate from neuronal
progenitors which ultimately gives rise to neurons. On the other
hand, glial progenitors are far more plastic and may give rise to
astrocytoma or glioblastoma (from astrocyte progenitor) or oligo-
dendroglioma (from oligodendrocyte progenitor). We refer the
readers to an excellent reviewonbrain cancer byHuse andHolland
(2010).
Medulloblastoma, one of the more common malignant brain
tumors in children which originates in the area between the
brainstem and the cerebellum, remains responsible for a signif-
icant level of morbidity and mortality among cancer patients. A
proposed pathway involved in the development of medulloblas-
toma is the sonic hedgehog (SHH) pathway (Weiner et al., 2002).
Approximately 15% of sporadic medulloblastomas present with
genomic alterations in components of the SHH signaling path-
way (Taylor et al., 2002). Normally, the SHH mitogen enables the
cerebellar granule neuron precursors (CGNPs) to exhibit rapid
cellular growth that eventually progresses to terminal differentia-
tion into glutamatergic neurons. Dysregulation of SHH activation
is implicated in medulloblastoma and its proliferative effects are
enabled by its transcription factor target, N-myc (Knoepﬂer and
Kenney, 2006). N-myc has been shown to be critical for normal
brain growth as well as being a key player in medulloblastoma.
Importantly, GSK3 is reported to be a regulator of N-myc phos-
phorylation (Knoepﬂer and Kenney, 2006). Phosphorylation of
N-myc leads to its destabilization and degradation. Thus, treat-
ment of CGNPs with LiCl or GSK3 chemical inhibitor leads to a
rapid decrease in N-myc phosphorylation. Furthermore, inhibi-
tion of PI3K leads to an increase in GSK3 activity resulting in a
rapid turnover of N-myc (Kenney et al., 2004). Thus, dysregula-
tion of GSK3 is a key player in medulloblastoma and targeting this
protein may be a novel therapeutic approach.
Inhibition of GSK3β activity also induces tumor cell differenti-
ation and enhances apoptosis in glioblastoma. Targeted inhibition
of GSK3β results in a decrease in progenitor markers while induc-
ing expression of GFAP, β-tubulin III, CNPase, all being cellular
differentiation markers. In addition, GSK3 inhibition has a neg-
ative effect on the subpopulation of cancer stem cell-like cells,
depleting them and pushing into differentiation. These observa-
tions strengthen the claim that GSK3 inhibition in glioma cells
results in decreased proﬁciency in anchorage-independent growth
compared to wild-type. Impairment in the formation of neu-
rospheres and decrease in stem cell markers are also observed
following GSK3β inhibition (Kotliarova et al., 2008; Korur et al.,
2009).
INDIRECT ROLES OF GSK3 IN CANCER
In addition to the aforementioned direct roles of GSK3 in cancer,
it may also indirectly be involved in cancer due to its participation
in dysregulated signaling pathways. For example, one of the major
upstream protein kinases known to phosphorylate and inactivate
GSK3 is protein kinase B (PKB)/AKT, which is often dysregu-
lated in tumors (Robinson et al., 2011). AKT is able to enhance
growth-factor mediated survival by multiple mechanisms. One
method is the phosphorylation of the pro-apoptotic protein,
BCL2-associated agonist of cell death (BAD), leading to inhibition
of complex formation between BAD and BCL-2. This dissocia-
tion causes a shift from apoptosis to cellular survival (Downward,
2004). Another possibility is the ability of AKT to activate NF-
κB by the non-canonical pathway involving activation of IKKα
which increases p53 production. This increase in NF-κB activ-
ity is implicated in transformation of murine ﬁbroblasts as well
as involvement in breast and skin cancers (Gustin et al., 2006).
Additionally, AKT promotes nuclear translocation of mouse dou-
ble minute 2 (MDM2), an E3 ubiquitin ligase, thereby down-
regulating p53-mediated apoptosis (Mayo and Donner, 2001).
The tumor suppressor phosphatase and tensin homolog (PTEN)
antagonizes this PI3K/Akt pathway. For example, in certain brain
cancers, PTEN dysfunction may contribute to the formation of
gliomas in multiple ways including having effects on stem cell
self-renewal, migration, invasion as well as by enhanced degra-
dation of p53 via increased expression of MDM2 (Endersby and
Baker, 2008).
Glycogen synthase kinase 3 can also phosphorylate the pro-
oncogenic molecules β-catenin, c-myc, and c-Jun, targeting them
for degradation or inactivation. This results in inhibition of cell
proliferation and self-renewal. Dysregulation in these pathways
and gain-of-function mutations in these three proteins interfere
with the function of GSK3 and have been linked to cancers of the
skin, colon, prostate, and liver (Polakis, 2007).
Dysregulation in the GSK3 pathway has also been implicated in
oral cancer. Tumor recurrence and metastasis pose a challenge to
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controlling this malignancy. Emerging research suggests a critical
role of GSK3β as a tumor suppressor in oral cancer. Further-
more, GSK3β may be vital in regulating key players that control
transcription, accelerated cell cycle progression, activation of inva-
sion/metastasis, and anti-apoptosis (Goto et al., 2002; Chien et al.,
2010; Iwai et al., 2010). P-cadherin triggers GSK3βmediated inac-
tivation and subsequent cytoplasmic translocation of Snail in oral
squamous cell carcinoma, thus conferring mesenchymal cells with
epithelial features (Bauer et al., 2009). These results contradict the
idea of GSK3 as a therapeutic target. However, as discussed below,
in a subset of cancers, GSK3 inhibition can induce death or halt
tumor progression.
Speciﬁcally, in brain tumors, GSK3β may have an indirect role
in glioblastomas which is one of the most lethal brain tumors.
Glioblastomas are notoriously difﬁcult to treat and have a median
survival time of∼14months. As mentioned above cancers are dri-
ven by cells with stem cell properties. Expression of GSK3β, which
is consistently expressed in primary glioblastoma, is functionally
linked to Bmi1, a protein involved in neural stem cell self-renewal
and anti-oxidant defense in neurons (Kotliarova et al., 2008; Korur
et al., 2009). Research has also shown that inhibition of Bmi1, a
member of the polycomb family of proteins, results in reduced
GSK3β as well as increased differentiation of glioma (Korur et al.,
2009). While fully differentiated normal brain tissue has no Bmi1
expression, it is marked in 84% of primary glioblastomas and
71% of primary oligodendroglioma. Downregulation of Bmi1 in
glioma cells results in an increase in cell differentiation toward an
astrocytic fate and a decrease in expression of Nestin, Sox2, and
GSK3β.
Furthermore, inactivation of GSK3α and GSK3β has been
reported to block differentiation in brain progenitor cells, and
instead lead to substantial hyperproliferation of the neural prog-
enitor cells, thus, expanding the population (Kim et al., 2009).
These observations were attributed to dysregulation of β-catenin,
SHH, Notch, and ﬁbroblast growth factor signaling. This critical
GSK3-mediated homeostatic control was only removed by amajor
reduction of GSK3 signaling. Since brain development requires a
balance of progenitor proliferation and differentiation this might,
in a more sporadic background, lead to ampliﬁcation of stem cells.
This may, at least theoretically, lead to subsequent tumor forma-
tion. Thus, GSK3 signaling is integral to homeostatic controls and
further dissection of these intricate processes will elucidate the
therapeutic role of GSK3 in cancer.
Another potential mechanism of GSK3 activation in cancer
may be via the epidermal growth factor receptor (EGFR) path-
ways. The EGFR family of proteins (EGFR/HER/ErbB2) plays an
essential role in modulating proliferation, differentiation, and sur-
vival. EGFR has become a heavily targeted pathway as a novel
cancer therapeutic strategy since its overexpression confers resis-
tance to therapy. It has also been recently reported that lapatinib,
a small molecule tyrosine kinase inhibitor targeting EGFR and
HER2, is associated with changes inAkt and GSK3 (Li et al., 2011).
Accordingly, EGFR and phosphorylated GSK3β have been vali-
dated as good prognostic markers for EGFR overexpressing lung
carcinoma (Zheng et al., 2007). Thus, it is intriguing to hypoth-
esize that there may be signiﬁcant cross-talk between GSK3 and
EGFR signaling pathways. Interestingly, dysregulation in the EGFR
family of proteins is observed in glioblastoma (Furnari et al., 2007;
Chin, 2008; Parsons et al., 2008; Bredel et al., 2011). The EGFR
signaling pathway may be activated alternatively via NF-κB and
can be repressed by the nuclear factor of κ-light polypeptide gene
enhancer in B-cells inhibitor-α (NFκBIA). It has been suggested
that NFκBIA may function as a tumor suppressor in multiple can-
cers (Osborne et al., 2005; Sjöblom et al., 2006; Bu et al., 2007). Not
surprisingly,NFκBIA is often deleted in glioblastomas and confers
resistance to chemotherapy (Bredel et al., 2011). Since NF-κB is
also known tobe an important player in the survival of glioma cells,
it is not surprising that attenuation of GSK3 inhibits NF-κB lead-
ing to decreased glioma cell growth (Kasuga et al., 2004; Robe et al.,
2004). TRAIL, DR4/5, and c-myc are induced upon GSK3 inhibi-
tion in a dose-dependent manner. Furthermore, GSK3 inhibition
has been reported to have synergistic effects in combination with
the chemotherapeutic drug, carboplatin, on glioma cytotoxicity.
Further evidence of this link lies in the signal transducer and
activator of transcription (STAT) family of transcription factors,
which is downstream of EGFR and plays a central role in cancer.
STAT3 is constitutively activated in many human cancers where
it functions as a critical mediator of oncogenic signaling through
transcriptional activation of genes encoding apoptosis inhibitors
[e.g., BCL-x(L) and survivin], cell-cycle regulators (e.g., cyclin D1
and c-myc) and inducers of angiogenesis (e.g., vascular endothe-
lial growth factor). The STAT3 gene has been reported to regulate
cancer stem cells in brain cancer. Importantly, GSK3 inhibitors
have been demonstrated to block STAT3 DNA binding activity
and reduce the expression of STAT3-induced Glial ﬁbrillary acidic
protein (GFAP) and B-cell CLL/lymphoma 3 (BCL-3; Beurel and
Jope, 2008).
The above ﬁndings suggest that GSK3 inhibition indeed may be
beneﬁcial in brain tumors. However, one must be cautioned and
consider the actions of GSK3 in normal neurons. Dysregulation
of GSK3 in a variety of brain abnormalities supports its function
as the switch between basic mechanisms of neuronal functions.
It plays a pivotal role in brain bioenergetics, establishment of
neuronal circuits, modulation of neuronal polarity, migration,
neuronal proliferation, and survival (Frame and Cohen, 2001). In
particular, the role of GSK3 inphosphorylationof cytoskeletal pro-
teins impacts neuronal plasticity. Since cytoskeletal constituents
are involved in the development and maintenance of neurites,
alterations in the rate of stabilization/destabilization of micro-
tubules inﬂuences major cellular compartments of neurons, such
as dendrites, spines, axons, and synapses. This modulates synap-
tic plasticity in the adult brain (Peineau et al., 2008). Due to the
effects of GSK3 on synaptic plasticity, the use of GSK3 inhibitors
for cancer therapy must be approached with caution. However, a
subset of cancer patientsmay beneﬁt fromGSK3 inhibition, due to
the paradoxical effect of GSK3 activity on tumor growth. Further
investigation to determine the full extent of GSK3 dysregulation
in cancer is thus warranted.
GSK3 INHIBITION AND PROTECTION OF IRRADIATED
NEURONS
Nevertheless, the role of GSK3 inhibition in brain tumor therapy
may extend beyond tumoricidal effects and provide neuroprotec-
tion following irradiation, which increases the therapeutic index
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and improves patient quality of life (Figure 3). Cranial irradiation
therapy is a standard method for treatment of brain cancer. Since
radiation cannot be selectively delivered to cancer cells, it leads to
many destructive cellular processes including apoptosis, genomic
instability, and autophagy. Cranial irradiation is known to cause
long-term cognitive defects especially in the developing brains of
children (Meadows et al., 1981). The subgranular zone of the hip-
pocampus, housing the actively proliferating neuronal progenitor
cells, is thought to be the area most affected by cranial irradiation
leading to neurocognitive deﬁcits (Nagai et al., 2000).
Interestingly, it has been known for some time that lithium
treatment has neuroprotective effects against various insults to
neuronal tissues (Nonaka et al., 1998; Cimarosti et al., 2001;
Hongisto et al., 2003). As previously mentioned, lithium is known
to modulate GSK3 activity by attenuating GSK3 activity at ther-
apeutic concentrations via the PI3K/AKT pathway (∼1mM; De
Sarno et al., 2002; Jope, 2003). These neuroprotective effects
of GSK3 inhibition have led to the hypothesis that GSK3 can
potentially be targeted to attenuate the side effects of cranial irra-
diation (Inouye et al., 1995; Yazlovitskaya et al., 2006; Thotala
et al., 2008). Treatment with LiCl increases phosphorylation of
GSK3β at S9 and concomitantly decreases the activating phos-
phorylation of GSK3β, GSK3β-T216. The major kinase respon-
sible for the inhibitory phosphorylation of GSK3 at S9 is Akt
which is activated upon LiCl treatment as well as treatment
with ionizing radiation. A two-fold increase in protein levels of
the downstream targets of GSK3, β-catenin, and cyclin D1, has
been reported following treatment with LiCl. Together these show
that LiCl treatment has a direct effect on GSK3 activity, which
may be explained by an increase in Akt activity. Importantly,
both lithium prophylaxis and prophylaxes with small molecule
FIGURE 3 | Inhibitors of GSK3 can selectively protect normal tissues
from radiation induced toxicities.
GSK3β inhibitors prior to cranial irradiation maintained neu-
rocognitive function in irradiated mice (Thotala et al., 2008).
Thus lithium can potentially improve neurocognitive function
following irradiation and the mechanism of action may be attrib-
uted to reduction of radiation-induced apoptosis of hippocampal
neurons.
While apoptosis is one consequence of this type of treatment,
radiation induced DNA damage is certainly another potential
trigger leading to neuronal death and subsequent neurocogni-
tive decline. There are multiple types of DNA damage that can
occur in a given cell, the most lethal and critical being the
double-strand break (DSB; Rich et al., 2000). There are two major
DSB repair pathways, homologous recombination (HR) and non-
homologous end-joining (NHEJ; van Gent et al., 2001). Cells with
radiation-induced DSBs utilize the NHEJ pathway predominantly.
During NHEJ-mediated repair, DNA-dependent protein kinase
catalytic subunit (DNA-PKcs) undergoes autophosphorylation
upon exposure to ionizing radiation. Thus, another mechanism
of neuroprotection by GSK3 inhibition may involve augmenting
DNA repair via one of these major repair pathways to attenuate
DNA damage.
Supporting this notion, GSK3 inhibition using LiCl selectively
augments DSB repair following IR in normal tissues but not can-
cer (Yang et al., 2009). Moreover, the accelerated repair of DSB in
normal tissues but not tumor involves the NHEJ-mediated repair
pathway.Theseﬁndings support the rationale for theuse of lithium
as a neuroprotector for normal cells exposed to ionizing radiation.
Since LiCl has multiple targets, neuroprotection via speciﬁc
inhibition of GSK3β was subsequently investigated. Thotala et al.
(2008) used speciﬁc GSK3β inhibitors or a kinase-inactive GSK3β
to show that GSK3β is indeed required for apoptosis and neu-
rocognitive decline in hippocampal neurons as a result of radiation
treatment. Additionally, it has been shown that GSK3 inhibition
using these selective inhibitors augment DSB repair following IR
in normal tissues but not cancer (Yang et al., 2011). Moreover, the
accelerated repair of DSB in normal tissues but not tumor involves
the NHEJ-mediated repair pathway. These results were validated
using genetic models as well and support the rationale for the use
of GSK3 inhibitors as neuroprotectors for normal cells exposed to
ionizing radiation.
The role of GSK3 in genomic instability is only recently gain-
ing attention. It follows that since LiCl and other inhibitors of
GSK3 exhibits neuroprotective effects manifesting as a decrease in
apoptosis resulting from radiation treatment, and DNA damage
is another known characteristic of radiation exposure, that GSK3
could potentially modulate DNA damage or repair. It should be
noted that lithium has its drawbacks as a neuroprotector. Besides
being non-speciﬁc, lithium requires a long 7-day prophylaxis, has
a narrow therapeutic window, and lacks speciﬁcity. Thus, it is not
feasible for the majority of brain tumors which require imme-
diate treatment. This necessitates efforts to discover novel GSK3
inhibitors that have greater therapeutic potential. Nevertheless,
several clinical trials have been initiated to test the efﬁcacy of
lithium in neuroprotection during the treatment of brain tumors
(Table 2). It should be noted that the trials are still in their early
stage. It remains to be seen if, indeed, lithium can improve the lives
of cancer patients.
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Table 2 | Lithium in clinical trials as a potential neuroprotector.
Institution Phase Trial Study population Treatment
NewYork University School of
Medicine
II NCT01105702 Newly diagnosed high grade glioma (WHO
Grade III and IV)
Temodar (Temozolomide), Bevacizumab,
lithium, and radiation for high grade glioma
Vanderbilt-Ingram Cancer
Center
I NCT00469937 –Histopathologically conﬁrmed extracranial
primary malignancy
Lithium duringwhole brain radiotherapy for
patients with brain metastases
–Multiple (i.e., >3) brain metastases OR<3
metastases with at least 1 metastasis
>4.0 cm in diameter
–Not eligible for radiosurgery
–No requirement for immediate whole-brain
radiotherapy
–No metastases to the midbrain or brainstem
Information from www.Clinicaltrials.gov accessed on August 1, 2011.
∗Italicized= completed trials.
It is perplexing that inhibition of GSK3 selectively upregulates
DNA repair in normal cells. One explanation may be that GSK3
is already maximally inhibited in the majority of cancer. It is also
intriguing to postulate that, perhaps, the status of p53 determines
cellular response to GSK3 inhibition. Perhaps, there are different
roles of GSK3 in p53 wild-type vs. mutated tumors and the p53-
independent component also mediates repair that is only apparent
whenp53 ismutated as is the case in themajority of cancer. Further
research is warranted in this avenue.
The mechanisms by which GSK3 is involved in DNA repair are
still forthcoming. Since GSK3 is implicated in several of the path-
ways that contribute to successful DNA repair, it is likely GSK3
could act as a direct regulator. One method could involve GSK3
interaction with key repair proteins. Our lab is currently explor-
ing this and other avenues to determine the full extent by which
GSK3 is involved DNA damage/repair and how this relates to
GSK3-induced neuroprotection. This has the potential to improve
the quality of life of cancer patients, especially in the pediatric
population.
SUMMARY AND CONCLUSION
Glycogen synthase kinase 3 is proving to be an even more com-
plex regulator of cellular function than was previously thought.
Its role in programmed cellular death pathways including apop-
tosis and autophagy as well as its effects on DNA damage/repair
and subsequent neuroprotection provide rationale for novel and
speciﬁc methods of targeting GSK3, especially for brain tumors.
This would be the ideal therapeutic strategy which would max-
imize the therapeutic index by promoting tumor cell kill while
protecting normal tissues. Nevertheless, the utility of GSK3 as a
therapeutic target must be approached with caution. Firstly, one
must verify the direction of GSK3 dysregulation as the impetus
for tumor development to ensure that beneﬁt can be realized with
GSK3 inhibition. Second, due to the effects of GSK3 on synaptic
plasticity in the adult brain, the use of GSK3 inhibitors for cancer
therapy must be approached with caution. Third, effects on both
peripheral tissue and tumor from using GSK3 inhibitor as neuro-
protector need to be teased out. Expression proﬁle and subcellular
localization of GSK3 in different cancers may provide a lead in
this aspect. Furthermore, since GSK3 has multiple critical roles in
cellular metabolism, inhibition of its activity may have unwanted
side effects. Further thorough evaluation is necessitated in this
ﬁeld before GSK3 can be embraced as a target for cancer therapy.
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